Enanta Pharmaceuticals' (ENTA) "Sector Perform" Rating Reiterated at Royal Bank of Canada
Royal Bank of Canada reaffirmed their sector perform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has a $54.00 target price on the biotechnology company’s stock. Several other analysts also recently weighed in on ENTA. Oppenheimer set a […]